Mupirocin resistance after long-term use for staphylococcus aureus colonization in patients undergoing chronic peritoneal dialysis

American Journal of Kidney Diseases

Volumn 39, Issue 2, 2002, Pages 337-341

  Perez Fontan, Miguel ^a   Rosales, Miguel ^a   Rodriguez Carmona, Ana ^a   Falcon, Teresa Garcia ^a   Valdes, Francisco ^a  

^a HOSPITAL JUAN CANALEJO   (Spain)

Author keywords

Mupirocin (Mup); Peritoneal dialysis (PD); Resistance; Staphylococcus aureus (SAu)

Indexed keywords

ANTIBIOTIC AGENT; GENTAMICIN; METICILLIN; OXACILLIN; PSEUDOMONIC ACID;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL COLONIZATION; BACTERIAL INFECTION; CATHETER INFECTION; CHRONIC KIDNEY DISEASE; FEMALE; HUMAN; KIDNEY DISEASE; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PERITONEAL DIALYSIS; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION;

EID: 0036180549     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/ajkd.2002.30553     Document Type: Article

References (24)

1. Staphylococcus aureus infections in dialysis patients. Focus on prevention
2. Treatment of staphylococcus aureus nasal carriers in CAPD with mupirocin: Long-term results
3. Staphylococcus aureus infection in hemodialysis patients. Mupirocin as topical strategy against nasal carriage. A review
4. A randomized trial of Staphylococcus aureus prophylaxis in peritoneal dialysis patients: Mupirocin calcium ointment 2% applied to the exit site versus cyclic oral rifampin
5. Adult peritoneal dialysis-related peritonitis treatment recommendations: 2000 Update
6. Mupirocin resistance in staphylococci
7. Evaluation of disc diffusion and Etest for determining the susceptibility of Staphylococcus aureus to mupirocin
8. The emergence of mupirocin resistance: A challenge to infection control and antibiotic prescribing practice
9. Antibacterial activity of Mupirocin (Pseudomonic acid), a new antibiotic for topical use
10. Mupirocin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use
11. New strategies for the use of mupirocin for the prevention of serious infections
12. Decrease in Staphylococcus aureus exit-site infections and peritonitis in CAPD patients by local application of muprocin ointment at the catheter exit-site
13. Application of mupirocin cream at the catheter exit site reduces exit-site infections and peritonitis in peritoneal dialysis patients
14. Mupirocin-resistant staphylococcus aureus
15. Mechanism of mupirocin transport into sensitive and resistant bacteria
16. Mupirocin resistance: Clinical and molecular epidemiology
17. Resistance to mupirocin: No indication of it to date while using mupirocin ointment for prevention of Staphylococcus aureus exit-site infections in peritoneal dialysis patients
18. Mupirocin resistance and methicillineresistant Staphylococcus aureus (MRSA)
19. Emergence of resistance during mupirocin treatment: Is it a problem in clinical practice
20. Clinical and economic effects of mupirocin calcium on preventing Staphylococcus aureus infection in hemodialysis patients: A decision analysis
21. Costeffectiveness of prophylactic nasal mupirocin in patients undergoing peritoneal dialysis based on a randomized, placebo-controlled trial
22. Treatment of peritonitis in CAPD with ciprofloxacin. Long term experience
23. Risk factors for persistent carriage of methicillin-resistant Staphylococcus aureus